OncoImmunology Q1区

期刊简介

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

肿瘤免疫学涉及自然或治疗诱导的癌症识别，以及肿瘤发生、炎症和免疫监视之间复杂的相互作用。我们现在创建了一个新的，高调的杂志，肿瘤免疫学，专门处理肿瘤免疫学。最近的进展已经允许抗癌免疫疗法的首次临床证明（和FDA批准）。人们还越来越怀疑-出乎意料地-许多目前使用的化疗剂的功效依赖于免疫效应子的积极贡献。用一个极端的比喻来说，成功应用化疗（或放疗）方案的肿瘤学家利用了免疫系统识别肿瘤特异性或肿瘤相关抗原的能力，并控制了癌（干）细胞的生长，而没有意识到无形的帮助之手。因此，免疫学生物标志物对于确定癌症的预后和预测化疗的功效变得越来越重要。同时，传统抗癌疗法与免疫疗法相结合也有很强的理论依据。OncoImmunology将接受肿瘤免疫学基础、转化和临床领域的高知名度投稿。欢迎提交有关实体癌或血液癌、炎症、先天性和获得性免疫反应的资料。

《OncoImmunology》期刊已被查看： 次

期刊官网投稿信息

分区信息

• 上一篇： NEUROSURGICAL REVIEW
• 下一篇：AIP Advances